{"id":"https://openalex.org/W4391442006","doi":"https://doi.org/10.1158/1078-0432.c.7054145","title":"Data from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors","display_name":"Data from First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors","publication_year":2024,"publication_date":"2024-02-01","ids":{"openalex":"https://openalex.org/W4391442006","doi":"https://doi.org/10.1158/1078-0432.c.7054145"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.7054145","doi":"https://doi.org/10.1158/1078-0432.c.7054145","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7054145","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1078-0432.c.7054145","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003770647","display_name":"Nehal J. Lakhani","orcid":"https://orcid.org/0009-0005-6327-0176","observed_orcids":["https://orcid.org/0009-0005-6327-0176"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nehal J. Lakhani","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0005-6327-0176","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073134832","display_name":"Drew Warren Rasco","orcid":"https://orcid.org/0009-0009-6619-2854","observed_orcids":["https://orcid.org/0009-0009-6619-2854"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Drew Rasco","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0009-6619-2854","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011940652","display_name":"Hengbang Wang","orcid":"https://orcid.org/0000-0003-3740-9056","observed_orcids":["https://orcid.org/0000-0003-3740-9056"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hengbang Wang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3740-9056","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080980717","display_name":"Lichuang Men","orcid":"https://orcid.org/0009-0007-5530-7869","observed_orcids":["https://orcid.org/0009-0007-5530-7869"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lichuang Men","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0007-5530-7869","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006831412","display_name":"Eric Liang","orcid":"https://orcid.org/0009-0008-5155-6662","observed_orcids":["https://orcid.org/0009-0008-5155-6662"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eric Liang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0008-5155-6662","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003741023","display_name":"Tommy Fu","orcid":"https://orcid.org/0009-0007-6486-2426","observed_orcids":["https://orcid.org/0009-0007-6486-2426"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tommy Fu","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-7586-8709","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038876039","display_name":"Mary C. Collins","orcid":"https://orcid.org/0000-0003-4282-9020","observed_orcids":["https://orcid.org/0000-0003-4282-9020"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mary C. Collins","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4282-9020","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077610145","display_name":"Ping Min","orcid":"https://orcid.org/0000-0002-5763-4253","observed_orcids":["https://orcid.org/0000-0002-5763-4253"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ping Min","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-5763-4253","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028456330","display_name":"Yan Yin","orcid":"https://orcid.org/0000-0003-1563-4666","observed_orcids":["https://orcid.org/0000-0003-1563-4666"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yan Yin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1563-4666","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-4529-2003","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085723739","display_name":"Dajun Yang","orcid":"https://orcid.org/0000-0002-6027-3604","observed_orcids":["https://orcid.org/0000-0002-6027-3604"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dajun Yang","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-6027-3604","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5021773274","display_name":"Yifan Zhai","orcid":"https://orcid.org/0000-0003-1672-2262","observed_orcids":["https://orcid.org/0000-0003-1672-2262"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yifan Zhai","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1672-2262","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.8859999775886536},{"id":"https://openalex.org/keywords/bcl-xl-inhibitors","display_name":"Bcl-xL inhibitors","score":0.9900000095367432},{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.6869999766349792},{"id":"https://openalex.org/keywords/small-cell-lung-cancer","display_name":"small cell lung cancer","score":0.7860000133514404},{"id":"https://openalex.org/keywords/metastatic-solid-tumors","display_name":"metastatic solid tumors","score":0.871999979019165},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.7289999723434448},{"id":"https://openalex.org/keywords/bax-bak","display_name":"Bax/Bak","score":0.8289999961853027},{"id":"https://openalex.org/keywords/caspases","display_name":"caspases","score":0.7329999804496765},{"id":"https://openalex.org/keywords/mcl-1","display_name":"Mcl-1","score":0.9639999866485596},{"id":"https://openalex.org/keywords/platelet-toxicity","display_name":"platelet toxicity","score":0.6480000019073486},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8759999871253967},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.503000020980835}],"concepts":[{"id":"https://openalex.org/C2993640289","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Solid tumor","level":3,"score":0.5724499225616455},{"id":"https://openalex.org/C3020497934","wikidata":"https://www.wikidata.org/wiki/Q17075943","display_name":"Precision oncology","level":3,"score":0.48355862498283386},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4300239384174347},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4260328710079193},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35758286714553833},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33477210998535156},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1621171534061432}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.7054145","doi":"https://doi.org/10.1158/1078-0432.c.7054145","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7054145","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.7054145","doi":"https://doi.org/10.1158/1078-0432.c.7054145","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.c.7054145","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4388729147","https://openalex.org/W3030985489","https://openalex.org/W4286298003","https://openalex.org/W3170396526","https://openalex.org/W4392913471","https://openalex.org/W2914195336","https://openalex.org/W2904937054","https://openalex.org/W3213348546","https://openalex.org/W2235978613","https://openalex.org/W2890018428"],"abstract_inverted_index":{"AbstractPurpose:":[0],"B-cell":[1],"lymphoma-extra-large":[2],"(BCL-xL)":[3],"regulates":[4],"apoptosis":[5],"and":[6,37,50,54,63,68,79,91,107,128,131,147,152,188,196,202,213,233],"is":[7,234],"an":[8,24],"attractive":[9],"anticancer":[10],"therapeutic":[11,191],"target.":[12],"However,":[13],"BCL-xL":[14,38,159],"inhibition":[15,165],"also":[16],"kills":[17],"mature":[18],"platelets,":[19],"hampering":[20],"clinical":[21,240],"development.":[22],"Using":[23],"innovative":[25],"prodrug":[26],"strategy,":[27],"we":[28],"have":[29],"developed":[30],"pelcitoclax":[31,53,97,144,171,184,229],"(APG-1252),":[32],"a":[33,120,221],"potent,":[34],"dual":[35],"BCL-2":[36],"inhibitor.":[39],"Aims":[40],"of":[41,52,59,158,200],"this":[42],"study":[43],"were":[44,73,105,217],"to":[45,75],"characterize":[46],"the":[47],"antitumor":[48,77,173,231],"activity":[49,78,133,174,232],"safety":[51,106],"explore":[55],"its":[56,238],"underlying":[57],"mechanisms":[58],"action":[60],"(MOA).":[61],"Patients":[62],"Methods:":[64],"Cell":[65],"line\u2013derived":[66],"xenograft":[67,70],"patient-derived":[69],"(PDX)":[71],"models":[72],"tested":[74],"evaluate":[76],"elucidate":[80],"MOA.":[81],"Subjects":[82],"(N":[83],"=":[84],"50)":[85],"with":[86,140,162,169,193,220,248],"metastatic":[87],"small-cell":[88],"lung":[89,151],"cancer":[90,136,154],"other":[92],"solid":[93,244],"tumors":[94],"received":[95],"intravenous":[96],"once":[98],"or":[99],"twice":[100],"weekly.":[101],"Primary":[102],"outcome":[103],"measures":[104],"tolerability;":[108],"preliminary":[109,190],"efficacy":[110],"(responses":[111],"every":[112],"2":[113],"cycles":[114],"per":[115],"RECIST":[116],"version":[117],"1.1)":[118],"represented":[119],"secondary":[121],"endpoint.":[122],"Results:":[123],"Pelcitoclax":[124],"exhibited":[125],"strong":[126],"BAX/BAK\u2012dependent":[127],"caspase-mediated":[129],"antiproliferative":[130],"apoptogenic":[132,142],"in":[134,150],"various":[135],"cell":[137,180],"lines.":[138],"Consistent":[139],"cell-based":[141],"activity,":[143],"disrupted":[145],"BCL-xL:BIM":[146],"BCL-xL:PUMA":[148],"complexes":[149,160],"gastric":[153],"PDX":[155],"models.":[156],"Levels":[157],"correlated":[161],"tumor":[163],"growth":[164],"by":[166,175],"pelcitoclax.":[167],"Combined":[168],"taxanes,":[170],"enhanced":[172],"downregulating":[176],"antiapoptotic":[177],"protein":[178],"myeloid":[179],"leukemia-1":[181],"(MCL-1).":[182],"Importantly,":[183],"was":[185],"well":[186,235],"tolerated":[187],"demonstrated":[189],"efficacy,":[192],"overall":[194],"response":[195],"disease":[197],"control":[198],"rates":[199],"6.5%":[201],"30.4%,":[203],"respectively.":[204],"Most":[205],"common":[206],"treatment-related":[207],"adverse":[208],"events":[209],"included":[210],"transaminase":[211],"elevations":[212],"reduced":[214],"platelets":[215],"that":[216,228,250],"less":[218],"frequent":[219],"once-weekly":[222],"schedule.":[223],"Conclusions:":[224],"Our":[225],"data":[226],"demonstrate":[227],"has":[230],"tolerated,":[236],"supporting":[237],"further":[239],"development":[241],"for":[242],"human":[243],"tumors,":[245],"particularly":[246],"combined":[247],"agents":[249],"downregulate":[251],"MCL-1.":[252]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2024-02-02T00:00:00"}